Diagnosing diseases is still a job best done by health professionals, but doctors might just become obsolete in the near future if devices like a newly-developed Breathalyzer keep popping up. By simply breathing into the device, up to 17 types of illnesses can be diagnosed with up to 86 percent accuracy.
Called the “Na-Nose,” the device is basically a nanoarray that’s powered by artificial intelligence. The researchers published the results of their study in ACS Nano detailing how the device can detect everything from certain types of cancer to irritable bowel syndrome.
“We report on an artificially intelligent nanoarray-based on molecularly modified gold nanoparticles and a random network of single-walled carbon nanotubes for noninvasive diagnosis and classification of a number of diseases from exhaled breath,” the paper reads. “The performance of this artificially intelligent nanoarray was clinically assessed on breath samples collected from 1404 subjects having one of 17 different disease conditions included in the study or having no evidence of any disease (healthy controls).”
The researchers also released a video, which explains how the device worked. Hossam Haick from the Technion-Israel Institute of Technology revealed that the whole point of the creation of the device was to catch diseases while the subject is still feeling healthy, Futurism reports.
This is certainly quite a step up in terms of early diagnosis of one of the 17 and hopefully, additional diseases in the future compared to how things are setup now. Most people don’t like going to the doctor for anything, especially male patients who would prefer waiting things out. By providing such people with a way to check if they have an illness without needing to deal with crowded clinics or unnecessary probing, catching serious health issues could become a lot easier.
On that note, such a future is still a long way off since an 86 percent diagnosis accuracy is still too low, USA Today reports. The device would need to be significantly more reliable before it can be used by the public.


Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 



